Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/38791
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCoffey, D.en
dc.contributor.authorKutko, M.en
dc.contributor.authorGlick, R.en
dc.contributor.authorButler, L.en
dc.contributor.authorHeller, G.en
dc.contributor.authorRifkind, R.en
dc.contributor.authorMarks, P.en
dc.contributor.authorRichon, V.en
dc.contributor.authorLaQuaglia, M.en
dc.date.issued2001en
dc.identifier.citationCancer Research, 2001; 61(9):3591-3594en
dc.identifier.issn0008-5472en
dc.identifier.issn1538-7445en
dc.identifier.urihttp://hdl.handle.net/2440/38791-
dc.description© 2001 American Association for Cancer Researchen
dc.description.abstractHistone deacetylase inhibitors (HDACIs) inhibit the growth of a variety of transformed cells in culture. We demonstrated previously that the hybrid-polar HDACI m-carboxycinnamic acid bis-hydroxamide (CBHA) induces apoptosis of human neuroblastoma in vitro and is effective in lower doses when combined with retinoids. The current study investigates the effect of CBHA on the growth of human neuroblastoma in vivo, both alone and in combination with all-trans retinoic acid (atRA), using a severe combined immunodeficiency-mouse xenograft model. CBHA (50, 100, and 200 mg/kg/day) inhibited growth of SMS-KCN-69n tumor xenografts in a dose-dependent fashion, with 200 mg/kg CBHA resulting in a complete suppression of tumor growth. The efficacy of 50 and 100 mg/kg CBHA was enhanced by the addition of 2.5 mg/kg atRA. This dose of atRA was ineffective when administered alone. Treatment was accompanied by mild weight loss in all groups except the lowest dose of CBHA. Our results suggest HDACIs alone or combined with retinoids may have therapeutic utility for neuroblastoma.en
dc.description.statementofresponsibilityDennis C. Coffey, Martha C. Kutko, Richard D. Glick, Lisa M. Butler, Glenn Heller, Richard A. Rifkind, Paul A. Marks, Victoria M. Richon, and Michael P. La Quagliaen
dc.language.isoenen
dc.publisherAmer Assoc Cancer Researchen
dc.source.urihttp://cancerres.aacrjournals.org/cgi/content/abstract/61/9/3591en
dc.subjectTumor Cells, Cultured; Animals; Humans; Mice; Mice, SCID; Neuroblastoma; Weight Loss; Cinnamates; Tretinoin; Histone Deacetylases; Growth Inhibitors; Histones; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Enzyme Inhibitors; Xenograft Model Antitumor Assays; Cell Division; Acetylation; Dose-Response Relationship, Drug; Drug Synergism; Femaleen
dc.titleThe histone deacetylase inhibitor CBHA inhibits growth of human neuroblastoma xenografts in vivo alone and synergistically with all-trans retinoic aciden
dc.typeJournal articleen
dc.identifier.rmid0020071649en
dc.identifier.pubid48235-
pubs.library.collectionMedicine publicationsen
pubs.verification-statusVerifieden
pubs.publication-statusPublisheden
dc.identifier.orcidButler, L. [0000-0003-2698-3220]en
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.